REVIEW

CABOZANTINIB IN COMBINATION WITH IMMUNOTHERAPY FOR ADVANCED RENAL CELL CARCINOMA AND UROTHELIAL CARCINOMA: RATIONALE AND CLINICAL EVIDENCE

Paulo Bergerot, Peter Lamb, Evelyn Wang, and Sumanta K. Pal

SMALL MOLECULE THERAPEUTICS

FGF401, A FIRST-IN-CLASS HIGHLY SELECTIVE AND POTENT FGFR4 INHIBITOR FOR THE TREATMENT OF FGF19-DRIVEN HEPATOCELLULAR CANCER

Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wattmann, Jacqueline Kinyamu-Akuanda, Heiko S. Schadl, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Muzakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R. Sellers, and Diana Graus Porta

AURORA A–SELECTIVE INHIBITOR LY3295668 LEADS TO DOMINANT MITOTIC ARREST, APOPTOSIS IN CANCER CELLS, AND SHOWS POTENT PRECLINICAL ANTITUMOR EFFICACY


SHORT- AND LONG-TERM EFFECTS OF CDK4/6 INHIBITION ON EARLY-STAGE BREAST CANCER

### Table of Contents

**LARGE MOLECULE THERAPEUTICS**

2331 **Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy**

2343 **Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy**
Mike W. Helms, Kerstin Jahn-Hofmann, Felix Gnerlich, Christiane Metz-Weidmann, Monika Braun, Gabriele Dietert, Petra Scheer, Kai Grandien, Joachim Theilhaber, Hui Cao, Timothy R. Wagenaar, Max M. Schnurr, Stefan Endres, Dmitri Wiederschain, Sabine Scheidler, Simon Rothenfuesser, Bodo Brunner, and Lars M. König

**CANCER BIOLOGY AND TRANSLATIONAL STUDIES**

2357 **Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer**
Caiyun Wang, Tao Wang, Dacheng Lv, Ling Li, Jinnan Yue, Hong-Zhuang Chen, and Lu Xu

2368 **Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers**

2381 **Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation**
Pankaj K. Singh, Amit A. Desurukhdar, Bhanu P. Venkatesulu, Xiaolin Li, Ramesh Tailor, John S. Bomalaski, and Sunil Krishnan

2394 **Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5-Inhibitor Complexes**
Rose-Laure Indorato, Sandeep K. Talapatra, Fangzhuhu Lin, Shozeb Haider, Simon P. Mackay, Frank Kozielski, and Dimitrios A. Skoufias

2407 **Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1**
Hong Zhu, Counge Wu, Ting Wu, Wen Xia, Shusheng Ci, Weiru He, Yilan Zhang, Lulu Li, Shiying Zhou, Jing Zhang, Ashlin M. Edick, Anna Zhang, Fei-Yan Pan, Zhigang Hu, Lingleng He, and Zhigang Guo

2421 **Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600E Mutant Melanoma Patient-Derived Xenografts**
Tianshu Feng, Javad Golji, Ailing Li, Xiamei Zhang, David A. Rudy, Daniel P. Rakiei, Felipe C. Geyer, Jane Gu, Hui Gao, Juliet A. Williams, Darrin D. Stuart, and Matthew J. Meyer

2433 **Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects**
Yin Huaiqi, Qin Caipeng, Wang Qiang, Du Yiqing, Dai Xiang, Tang Xu, Zhang Xiaowei, Li Qing, Liu Shijun, and Xu Tao

2446 **Hyaluronic Acid Binding to TLR4 Promotes Proliferation and Blocks Apoptosis in Colon Cancer**
Sarbjeet Makkar, Terrence E. Richl, Baosheng Chen, Yan Yan, David M. Alvarado, Matthew A. Giordano, and William F. Stenson

2457 **Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3β Pathway**
Leichao Liu, Ti Meng, Xiaowei Zheng, Yang Liu, Ruifang Hao, Yan Yan, Siying Chen, Haisheng You, Jianfeng Xing, and Yalin Dong
Pancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lead to cell death. To achieve this, a polyethylene glycol (PEG)-conjugated arginine deiminase construct (ADI-PEG20) was previously designed and tested as a monotherapy in clinical studies with limited success. In the cover image, adapted from Figure 3 of the associated manuscript, Singh and colleagues demonstrate ADI-PEG20 radiosensitized pancreatic cancer cells by inducing ER stress (red fluorescence, BIP). Therefore, ADI-PEG20 could be combined with radiation therapy in patients whose tumors are arginine-dependent. Read the full study on page 2381.